search
Back to results

Anxiolysis for Laceration Repair in Children (ALICE)

Primary Purpose

Laceration of Skin, Distress, Emotional

Status
Not yet recruiting
Phase
Phase 3
Locations
Canada
Study Type
Interventional
Intervention
Dexmedetomidine
Midazolam Nasal Spray
Nitrous oxide
Sponsored by
Lawson Health Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Laceration of Skin

Eligibility Criteria

2 Years - 12 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 2-12.99 years (maximum 65 kg to avoid underdosing of intranasal interventions)
  • Single laceration requiring simple interrupted sutures alone
  • No concomitant fracture or dislocation
  • Repair to be performed by the emergency physician or their designate
  • Child or caregiver desires anxiolysis for laceration repair
  • Local anesthesia planned to involve only topical LET and/or infiltrated lidocaine
  • American Society of Anesthesiologists (ASA) Class I (healthy) or II (mild to moderate systemic disease that is medically well controlled, e.g. asthma or type II diabetes mellitus)

Exclusion Criteria:

  • Opioid, sedative, or anxiolytic medication administered < 24 hours prior to procedure
  • History of hypersensitivity to dexmedetomidine, midazolam, or nitrous oxide
  • Occlusion of at least one nare due to mucus, polyps, septal deviation, or foreign body
  • Bradycardia or hypotension below two standard deviations (SD) of age-related normal value
  • Pre-existing renal insufficiency, uncorrected mineralocorticoid deficiency (e.g. congenital adrenal hyperplasia), pulmonary hypertension, uncorrected cyanotic congenital heart disease, cardiac conduction disorder, pulmonary hypertension, pulmonary edema, vitamin B12 (cobalamin) or folate deficiency or disorders, phenylketonuria, or psychotic disorder
  • Impaired level of consciousness (e.g. due to head injury, toxin ingestion, or post-ictal state)
  • Conditions associated with potential accumulation of gas within body spaces
  • Suspected cardiorespiratory instability or cardiac ischemia,
  • Suspected pregnancy
  • Inability to vocalize pain due to motor deficits
  • Caregiver in attendance unable to read or understand English or French in the absence of a native language interpreter

Sites / Locations

  • London Health Sciences Centre

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Intranasal dexmedetomidine

Intranasal midazolam

Inhaled nitrous oxide

Arm Description

IN dexmedetomidine 3 mcg/kg [100 mcg/mL (max 200 mcg or 2 mL)]

IN midazolam 0.4 mg/kg [5 mg/mL (max 10 mg or 2 mL)]

50% N2O in 50% oxygen by face mask or on-demand system

Outcomes

Primary Outcome Measures

Observational Scale of Behavioral Distress - Revised (OSBD-R)
Score ranges from 0 (no distress) to 23.5 (maximal distress) and will be scored for the time interval encompassing preparation, suturing, and recovery

Secondary Outcome Measures

Adverse effects
Will be based on the Quebec Guidelines and Health Canada reporting standards for sedation in children and include nausea and vomiting
Need for additional anxiolysis or sedation to facilitate repair
Need for additional anxiolysis or sedation to facilitate repair
Need for physical restraint
Need for restraint during preparation and suturing based on the Procedural Restraint Intensity in Children (PRIC) scale. The PRIC is scored in discrete integer values from 0=no restraint to 4=extreme forceful restraint. A higher score indicates more restraint is needed.
Late maladaptive behaviors
Late maladaptive behaviors up to an including 72 hours post discharge using the Post-Hospital Behavior Questionnaire. The scale consists of 27 items concerning sleep, eating, anxiety, etc. where each item is scored from 1-5. The minimum score is 27 and the maximum score is 135 with higher scores indicating greater severity of behaviors.

Full Information

First Posted
May 10, 2022
Last Updated
September 26, 2023
Sponsor
Lawson Health Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT05383495
Brief Title
Anxiolysis for Laceration Repair in Children
Acronym
ALICE
Official Title
Anxiolysis for Laceration Repair in Children: A Multicenter Adaptive Randomized Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 15, 2023 (Anticipated)
Primary Completion Date
December 31, 2025 (Anticipated)
Study Completion Date
December 31, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lawson Health Research Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a 3-arm adaptive clinical trial to the optimal light sedative for reducing distress during laceration repair in children. The investigators will compare intranasal (IN) dexmedetomidine, IN midazolam, and nitrous oxide (N20). The primary outcome is the Observational Scale of Behavioral Distress - Revised (OSBD-R).
Detailed Description
Accounting for almost half of all procedures performed, lacerations are the most common reason for an ED visit in children. There is consistent evidence that children experience considerable distress during laceration repair, despite routine application of topical anesthetic, lidocaine-epinephrine-tetracaine (LET). Certified child life specialists (CCLSs) can help children cope with distress but are not widely available. Untreated distress in childhood can lead to anxiety, needle phobia, and fear of medical care as adults. The American Academy of Pediatrics and American Academy of Pediatric Dentistry strongly recommend minimizing discomfort and controlling behavior and movement during procedures but there is no specific guidance on laceration repair. Many children require pharmacologic anxiolysis for laceration repair but evidence for the most effective agent is lacking. Although anxiolytics such as midazolam and nitrous oxide (N2O) are frequently used, there are drawbacks including variable efficacy and nasal irritation in the case of midazolam and lack of cooperation in younger children in the case of N2O. IN dexmedetomidine is a potentially effective anxiolytic for laceration repair that could overcome these limitations. IN dexmedetomidine is a relatively new anxiolytic with sedative and analgesic properties. It is tasteless, non-irritative, and highly concentrated (100 mcg/mL). A maximum dose of 200 mcg/2 mL can be given with 2 pairs of 0.5 mL IN sprays. The investigator's team published a systematic review of IN dexmedetomidine for distressing procedures. It was well tolerated by more than 90% of children and provided adequate anxiolysis in more children (79%) versus conventional anxiolytics (midazolam, chloral hydrate) (60%). Only one trial investigated IN dexmedetomidine in children for laceration repair and 70% were deemed "not anxious" compared to IN midazolam (11%). However, the study focused on initial positioning rather than repair. For proof of concept and to identify the optimal dose and feasibility of IN dexmedetomidine, we completed a pilot of 55 children undergoing laceration repair. All children tolerated IN administration, the consent rate was 82%, and there were no serious adverse events (AE). A dose of 3 mcg/kg balanced efficacy with duration of sedation, in line with others' findings. Oral midazolam is the most common anxiolytic for laceration repair in children. However, onset and duration of action and efficacy can be unreliable and its bitter taste leads to poor compliance. IN midazolam using a mucosal atomizer device (MAD) is increasingly popular because it overcomes these limitations. Compared to oral midazolam, IN midazolam has a shorter onset of action (28 vs 34 minutes) but causes nasal irritation in up to 40% of patients. In addition, IN midazolam has variable efficacy for laceration repair and more adverse effects compared to nitrous oxide or IN dexmedetomidine. The largest study of IN midazolam was a retrospective study of combination IN midazolam plus fentanyl. A lower dose of midazolam (0.2 mg/kg) resulted in fewer adverse effects (0.7%) than with higher doses (2-5%). Adding IN fentanyl provided superior efficacy where only 2.4% of patients experienced a treatment failure. The second most common anxiolytic is inhaled N2O, a tasteless gas that is administered in a concentration of 30-70% with oxygen. N2O is safe and effective for minor painful procedures. Peak effect is rapid (2 minutes) and effects dissipate quickly (3 minutes) upon discontinuation. Minor adverse effects occur in less than 10% of patients. However, based on the United Kingdom National Clinical Guideline Centre, it's unclear whether uncooperative children will comply with N2O administration. The investigators' recently completed systematic review of 29 trials of N2O for painful procedures in children found 50% N2O was superior to subcutaneous lidocaine, placebo, and oral midazolam. Only 5 trials focused on laceration repair but they were small and limited by non-validated or no measures of anxiety . Despite frequent use of anxiolytics such as midazolam and N2O, The investigators' national survey found that 80% of Canadian paediatric ED physicians strongly believed that "children experience significant enough distress to warrant anxiolysis" and it would "improve the patient care experience". To improve care, a rigorous trial of a novel anxiolytic, IN dexmedetomidine, and dissemination of the research findings is needed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Laceration of Skin, Distress, Emotional

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Phase III, multicentre, open-label, randomized, three-arm, adaptive trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
300 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intranasal dexmedetomidine
Arm Type
Experimental
Arm Description
IN dexmedetomidine 3 mcg/kg [100 mcg/mL (max 200 mcg or 2 mL)]
Arm Title
Intranasal midazolam
Arm Type
Experimental
Arm Description
IN midazolam 0.4 mg/kg [5 mg/mL (max 10 mg or 2 mL)]
Arm Title
Inhaled nitrous oxide
Arm Type
Experimental
Arm Description
50% N2O in 50% oxygen by face mask or on-demand system
Intervention Type
Drug
Intervention Name(s)
Dexmedetomidine
Other Intervention Name(s)
Precedex
Intervention Description
Intranasal dexmedetomidine 3 mcg/kg [100 mcg/mL (max 200 mcg or 2 mL)
Intervention Type
Drug
Intervention Name(s)
Midazolam Nasal Spray
Other Intervention Name(s)
Versed
Intervention Description
Intranasal midazolam 0.4 mg/kg [5 mg/mL (max 10 mg or 2 mL)
Intervention Type
Drug
Intervention Name(s)
Nitrous oxide
Other Intervention Name(s)
Nitronox
Intervention Description
50% nitrous oxide in 50% oxygen by face mask
Primary Outcome Measure Information:
Title
Observational Scale of Behavioral Distress - Revised (OSBD-R)
Description
Score ranges from 0 (no distress) to 23.5 (maximal distress) and will be scored for the time interval encompassing preparation, suturing, and recovery
Time Frame
During preparation, suturing, and recovery (20 minutes)
Secondary Outcome Measure Information:
Title
Adverse effects
Description
Will be based on the Quebec Guidelines and Health Canada reporting standards for sedation in children and include nausea and vomiting
Time Frame
From intervention to 72 hours post-discharge
Title
Need for additional anxiolysis or sedation to facilitate repair
Description
Need for additional anxiolysis or sedation to facilitate repair
Time Frame
During suturing (10 minutes)
Title
Need for physical restraint
Description
Need for restraint during preparation and suturing based on the Procedural Restraint Intensity in Children (PRIC) scale. The PRIC is scored in discrete integer values from 0=no restraint to 4=extreme forceful restraint. A higher score indicates more restraint is needed.
Time Frame
During preparation and suturing (10 minutes)
Title
Late maladaptive behaviors
Description
Late maladaptive behaviors up to an including 72 hours post discharge using the Post-Hospital Behavior Questionnaire. The scale consists of 27 items concerning sleep, eating, anxiety, etc. where each item is scored from 1-5. The minimum score is 27 and the maximum score is 135 with higher scores indicating greater severity of behaviors.
Time Frame
From discharge to 72 hours post-discharge
Other Pre-specified Outcome Measures:
Title
Compliance with intervention administration
Description
Compliance (percent of calculated IN volume given and acceptance of face mask or on-demand mouthpiece (yes/no))
Time Frame
From drug administration through completion of suturing (40 minutes)
Title
Caregiver satisfaction with anxiolysis during laceration repair
Description
Caregiver satisfaction with anxiolysis (5-item Likert scale ranging from 1=very unsatisfied to 5=very satisfied). A higher score indicates greater satisfaction.
Time Frame
At discharge (1 minute)
Title
Child satisfaction with anxiolysis during laceration repair
Description
Child (7-12 years) satisfaction with anxiolysis (5-item Likert scale ranging from 1=very unsatisfied to 5=very satisfied). A higher score indicates greater satisfaction.
Time Frame
At discharge (1 minute)
Title
Healthcare provider (physician, nurse, respiratory therapist) satisfaction with anxiolysis during laceration repair
Description
Nurse, physician, parent, and child 7-12 years satisfaction with anxiolysis (5-item Likert scale ranging from 1=very unsatisfied to 5=very satisfied). A higher score indicates greater satisfaction.
Time Frame
During recovery (1 minute)
Title
Number of healthcare personnel required during repair
Description
Maximum number of healthcare personnel required at bedside during repair to provide physical restraint or patient care
Time Frame
During procedure (10 minutes)
Title
Cost of healthcare personnel required at bedside during repair
Description
Costs of healthcare personnel based on salary per minute required at bedside during repair to provide physical restraint or patient care
Time Frame
During procedure (40 minutes)
Title
Cost of interventions
Description
Cost of interventions based on group assignment
Time Frame
During procedure (40 minutes)
Title
Total ED length of stay
Description
ED length of stay
Time Frame
During emergency department visit (2 hours)
Title
Duration of procedure
Description
Duration of laceration repair
Time Frame
During procedure (40 minutes)
Title
Post-intervention length of stay
Description
Length of stay due to anxiolytic
Time Frame
From drug administration to discharge (80 minutes)
Title
Nasal irritation
Description
Nasal irritation due IN intervention using the FLACC scale. Measured following IN sprays
Time Frame
During IN intervention administration (2 minutes)
Title
Post-procedure length of stay
Description
Post-procedure length of stay
Time Frame
From suturing to discharge (40 minutes)
Title
Caregiver state anxiety
Description
Caregiver anxiety related to laceration repair using State Trait Anxiety Inventory Short version - State (STAIS5)
Time Frame
Immediately prior to Phase II (preparation) (1 minute)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: i) Age 2-12.99 years [ ii) Single laceration for which the treating physician believes repair does not require IV sedation iii) Repair to involve sutures and performed by ED physician or designate (trainee) iv) Child or caregiver desires anxiolysis for laceration repair [justification: incorporates family preferences based on their prior experiences or beliefs about child's response] vii) Local anesthesia planned to involve topical anesthetic (LET) +/- infiltrated lidocaine Exclusion Criteria: i) Sedative, anxiolytic, or alpha-2-adrenergic receptor agonist < 24 hours prior to interventions (may compound sedative effect and increase the SAE risk). 24-hours encompasses the duration of sedation of most agents. ii) Hypersensitivity to any intervention iii) Occlusion of > 1 nostril due to polyps, septal deviation, or foreign body (may prevent drug absorption) iv) Hemodynamic abnormalities: bradycardia or hypotension < 2 SD of age-related normal value v) IND contraindications: Pre-existing renal insufficiency, uncorrected mineralocorticoid deficiency, pulmonary hypertension, uncorrected cyanotic heart disease, cardiac conduction disorder, pulmonary hypertension, pulmonary edema, vitamin B12 or folate disorder, phenylketonuria, or psychosis vi) Sedation contraindications: Impaired level of consciousness or respiratory instability vii) N2O contraindications: Conditions associated with potential accumulation of gas within body spaces viii) Suspected pregnancy (as reported by patient) ix) Inability to vocalize pain due to motor deficits (unable to apply the OSBD-R) x) Caregiver unable to complete study tasks due to insufficient comprehension of either English or French in the absence of a native language interpreter xi) Weight >= 65 kg (to avoid under-dosing of INM or IND) x) Not American Society of Anesthesiologists class I (healthy) or II (controlled mild to moderate disease) xii) No concomitant fracture or dislocation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Naveen Poonai, MD
Phone
5196858500
Ext
52011
Email
naveen.poonai@lhsc.on.ca
Facility Information:
Facility Name
London Health Sciences Centre
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 5W9
Country
Canada
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Naveen Poonai, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Anxiolysis for Laceration Repair in Children

We'll reach out to this number within 24 hrs